OPEN COMPANY INTELLIGENCEPublicly Listed Biopharma · Companies
Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
1Arvinas is a U.S. clinical-stage biotechnology company developing medicines based on targeted protein degradation. Its PROTAC platform is designed to use cellular protein-disposal machinery to reduce selected disease-associated proteins. Research priorities include oncology and neuroscience, with programs intended to assess potential therapeutic uses of selective protein degradation. Arvinas is headquartered in New Haven, Connecticut, and its common stock trades on Nasdaq under ARVN. The company combines proprietary discovery technologies with clinical-development work and selected partnerships.
2Chugai Pharmaceutical is a Japan-based research-driven pharmaceutical company developing and commercializing medicines, particularly in areas requiring specialized biological and molecular approaches. Its R&D capabilities include therapeutic antibodies and small molecules across oncology, immunology, hematology and additional specialty disease areas. Chugai is headquartered in Tokyo and its shares trade on the Tokyo Stock Exchange under 4519. The company is affiliated with the Roche group while remaining a separately listed issuer, so its securities should not be merged into Roche's record.
3Hansoh Pharmaceutical Group is a listed pharmaceutical company based in China with substantial research, development and commercialization activities. The company develops innovative small-molecule and biological medicines and also operates a broader pharmaceutical business. Its official website describes oncology, central nervous system disorders, metabolic conditions, infections and immunology among its therapeutic areas. The corporate site identifies its Hong Kong stock code and offers links to its ongoing research and investor information. This entry focuses on the listed issuer and its enduring drug-development capabilities, rather than reproducing a rapidly changing inventory of products, research assets or financial results.
4Shenzhen Salubris Pharmaceuticals is a China-based pharmaceutical company engaged in research, development and commercialization of treatments for serious chronic diseases. Its original drug development emphasizes cardiovascular and related conditions, including programs in blood-pressure control, kidney disease and other areas with unmet medical needs. The company combines marketed medicines with research platforms intended to generate new therapies. Salubris trades on the Shenzhen Stock Exchange under stock code 002294 and is headquartered in Shenzhen.
5D&D Pharmatech is a South Korea-based biotechnology developer focusing on investigational medicines for metabolic and other serious diseases. Its official site describes GLP-1 peptide-based treatments and oral peptide technologies alongside global clinical development efforts. The Korean Financial Supervisory Service company record identifies the issuer as D&D Pharmatech Inc., KOSDAQ code 347850, with an office in Seongnam. This directory records the listed parent and platform-level focus without attempting to maintain every clinical asset or licensing territory. The company’s official pipeline and investor materials provide up-to-date development information.
6Novartis is a Switzerland-based innovative medicines company active in the discovery, development, manufacture and commercialization of prescription treatments. Its official therapeutic-area pages identify cardiovascular, renal and metabolic conditions, immunology, neuroscience and oncology as major areas of focus. It employs multiple therapeutic technologies rather than a single drug-development platform. Official investor materials list ordinary shares on SIX Swiss Exchange under NOVN and American depositary receipts on the New York Stock Exchange under NVS.
7Biogen is a U.S. biotechnology company engaged in the research, development and commercialization of therapies for serious neurological and related diseases. Its research activities span several medicinal modalities, including biologics and other targeted approaches, supported by clinical-development and commercial capabilities. The company is headquartered in Cambridge, Massachusetts, and its shares trade on Nasdaq under BIIB. Biogen has a long-standing focus on neuroscience, while its clinical and commercial activities also extend into immunology and selected rare diseases.
8AstraZeneca is a United Kingdom-based, science-led pharmaceutical company engaged in discovering, developing and commercializing prescription medicines. Its research and business span oncology, biopharmaceutical medicines and rare diseases, using several treatment technologies and discovery platforms. The company reports its activities through an official corporate and investor website rather than maintaining a fixed product catalogue in this directory. Its investor FAQ confirms the AZN symbol across the London Stock Exchange, Nasdaq Stockholm and New York Stock Exchange, which are securities of the same corporate issuer.
9Novo Nordisk is a Denmark-based pharmaceutical company best known for developing and supplying medicines for diabetes, obesity and other serious chronic conditions. Its therapeutic capabilities include peptide and protein-based treatments alongside clinical development and manufacturing. Official investor material lists B shares on Nasdaq Copenhagen and American depositary receipts on the New York Stock Exchange under NVO. These listings refer to the same group and should be mapped as a single issuer.
10Astellas Pharma is a Japan-headquartered pharmaceutical company engaged in research, development, manufacturing and commercialization of prescription medicines. Its global operations combine pharmaceutical discovery with clinical development and external research partnerships. The company's therapeutic interests include oncology, transplantation and selected specialty diseases, and its development work spans small molecules and advanced therapeutic technologies. Astellas is based in Tokyo and its shares are listed on the Tokyo Stock Exchange under code 4503.
11Moderna is a U.S. biotechnology company developing medicines using messenger RNA technology and related delivery and manufacturing capabilities. Its platform supports the design and production of RNA-based therapeutics and vaccines, with research extending beyond infectious disease into oncology and selected other conditions. Moderna is headquartered in Cambridge, Massachusetts, and its common shares are listed on Nasdaq under MRNA. The company's scientific strategy combines sequence design, drug delivery, clinical development and commercial-scale production.
12C4 Therapeutics is a U.S. clinical-stage biotechnology company developing small-molecule medicines based on targeted protein degradation. Its platform is designed to identify molecules capable of directing selected disease-associated proteins toward cellular degradation mechanisms. The company primarily works in oncology, including hematologic malignancies, and seeks to apply degradation science to well-defined biological targets. C4 Therapeutics is headquartered in Watertown, Massachusetts, with shares listed on Nasdaq under CCCC. Its drug discovery strategy combines molecular design, cellular biology and translational research. The intended therapeutic approach differs from conventional inhibition because it seeks to reduce the abundance of a targeted protein.
13Biohaven is a clinical-stage biopharmaceutical company developing medicines for a range of neurological, immunological and oncological conditions. Its research includes extracellular protein degradation, other targeted therapeutics and selected antibody-drug conjugate programs. The company maintains research and development activities intended to translate disease mechanisms into drug candidates for rare and more common disorders. Biohaven is listed on the New York Stock Exchange under BHVN and has its corporate presence in New Haven, Connecticut. This concise entry identifies the company and its broad platform and therapeutic areas.
14BioNTech is a Germany-based biotechnology company focused on immunotherapies and other innovative treatments. Its research includes messenger RNA technologies, engineered immune approaches and additional modalities intended for cancer and infectious diseases. The company combines internal discovery and clinical development with manufacturing capabilities and external research collaborations. BioNTech maintains investor relations materials for its Nasdaq-listed securities and publishes updates about therapeutic and vaccine development on its official website. Its platform research connects genetic medicines with oncology and infectious disease applications.
15Hinova Pharmaceuticals is a China-based company involved in innovative medicine discovery, development and commercialization. Its research interests include oncology, metabolic disorders, autoimmune diseases and chronic inflammatory conditions. The company pursues small-molecule therapeutic approaches and differentiated drug-development strategies. Its official website identifies its Shanghai STAR Market securities code as 688302. Hinova's pharmaceutical activities encompass research into disease biology, candidate selection and clinical development, alongside industrialization planning for drug products. Its therapeutic focus differentiates the company from manufacturers solely producing established generic medicines or organizations limited to contract research services. The company operates within China's publicly listed innovative-drug development sector.
16BeOne Medicines develops and commercializes cancer treatments, combining internal discovery with clinical development and global commercialization. The company works across hematologic malignancies and solid tumors and uses a portfolio of therapeutic approaches rather than a single modality. Its official annual report identifies the same issuer across Nasdaq, Hong Kong and Shanghai listings; these securities must be stored under one company identity, not as separate companies. Its therapeutic development spans targeted oncology medicines and biologic treatment approaches.
17Kintor Pharmaceutical is a Chinese drug-development company working on targeted treatments for dermatological and other diseases. Its therapeutic research has included androgen-receptor-directed compounds, topical treatments for androgenetic alopecia, and experimental approaches aimed at oncology targets. Kintor is publicly listed in Hong Kong under stock code 9939. While the group also describes work involving dermatology-related cosmetic ingredients, that activity is distinct from its investigational therapeutic drug programs. The company maintains research and development operations in Suzhou and provides updates through its corporate website and stock-exchange disclosures.
18Arcturus Therapeutics Holdings is a U.S.-based RNA medicines company focused on developing nucleic-acid therapeutics and related delivery technology. Its platform capabilities include messenger RNA, self-amplifying RNA and lipid-mediated delivery, supported by manufacturing and formulation expertise. The company is based in San Diego, California, and trades on Nasdaq under ARCT. Research efforts address liver-related genetic conditions, respiratory diseases and other opportunities for RNA-based medicines. Its platform also has relevance to vaccine applications. This entry concentrates on company identity, technology and broad therapy areas, rather than tracking every clinical study or commercial arrangement.
19Bristol Myers Squibb is a U.S. biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines. Its therapeutic platforms include small-molecule drugs, biologic medicines and cell therapies, supported by internal research and external collaborations. Key areas of focus include oncology, immunology and cardiovascular disease. The company's common shares trade on the New York Stock Exchange under BMY. As a global pharmaceutical developer, it operates across multiple stages of research, clinical evaluation and commercial supply.
20Roche Holding is a Switzerland-based healthcare group with both pharmaceuticals and diagnostics divisions. It is included here because Roche Pharmaceuticals researches, develops and commercializes innovative treatments, not because its diagnostics business alone qualifies. Corporate material highlights areas including oncology, neuroscience, immunology, ophthalmology, and cardiovascular and metabolic diseases. The company also offers multiple classes of securities, including Swiss bearer shares and participation certificates and an OTC-traded American depositary receipt. These instruments should be represented under one legal issuer rather than as independent biotechnology companies.
21Sanofi is a France-based global biopharmaceutical company active in researching, developing and commercializing innovative medicines and vaccines. Its broad scientific capabilities cover immunology, rare diseases and other therapeutic areas, supported by internal platforms and external research collaborations. The official share-information page confirms ordinary shares on Euronext Paris under SAN and Nasdaq-listed American depositary shares under SNY; these are instruments of the same issuer. Its scientific organization encompasses biologics, vaccines and therapies for immune-related conditions.
22Daiichi Sankyo is a Japanese global pharmaceutical company researching, developing and commercializing prescription medicines. Its R&D activities include small molecules, biologic approaches and antibody-drug conjugate technologies, with significant work in oncology and selected cardiovascular and specialty diseases. The company maintains research and commercial operations internationally and collaborates with other drug developers. Headquartered in Tokyo, Daiichi Sankyo is listed on the Tokyo Stock Exchange under securities code 4568. This profile is intended as a stable directory description, not as an exhaustive catalog of products, treatment indications or clinical phases.
23Alnylam Pharmaceuticals is a United States biopharmaceutical company focused on the discovery, development and commercialization of medicines based on RNA interference. Its technology is designed to reduce production of selected disease related proteins through gene silencing. The company develops and markets therapeutics for serious conditions, including rare genetic and cardiovascular diseases, and collaborates with other pharmaceutical companies in selected programs. Founded in 2002, Alnylam is headquartered in Cambridge, Massachusetts. Its official website and investor relations pages provide information on currently marketed medicines, investigational programs, scientific publications and corporate disclosures.
24Ionis Pharmaceuticals is a United States company focused on medicines that target RNA to address serious diseases. Its research and marketed medicines draw on oligonucleotide technologies, including antisense approaches that can change production or processing of disease related proteins. Its therapeutic areas include neurological and cardiometabolic conditions, alongside selected rare diseases. Founded in 1989, Ionis is headquartered in Carlsbad, California, and has conducted public trading under the Nasdaq ticker IONS. Several medicines are developed independently and through partnerships.
Coverage expands from sourced records; this database does not claim all biopharma companies.
